

AMENDMENTS TO THE CLAIMS

1-3. (Cancelled)

4. (Currently Amended) The method of claim ~~[[1]]~~ 34, wherein treating comprises ~~reversing~~ reducing the effects resulting from the mis-splicing of the Clcn1 skeletal muscle chloride channel.

5. (Currently Amended) The method of claim ~~[[1]]~~ 34, wherein treating comprises ~~reversing the~~ reducing the effects resulting from mis-splicing of the Amyloid beta (A4) precursor protein (APP).

6. (Currently Amended) The method of claim ~~[[1]]~~ 34, wherein treating comprises ~~reversing the~~ reducing the effects resulting from mis-splicing of the NMDA receptor NR1 (GRIN1).

7. (Currently Amended) The method of claim ~~[[1]]~~ 34, wherein treating comprises ~~reversing the~~ reducing the effects resulting from mis-splicing of the Microtubule-associated protein tau (MAPT).

8. (Currently Amended) The method of claim ~~[[1]]~~ 34, wherein treating comprises ~~reversing the~~ reducing the effects resulting from mis-splicing of the TNNT2 (cTNT) protein.

9. (Cancelled)

10. (Currently Amended) The method of claim ~~[[1]]~~ 34, wherein the ~~mammal~~ subject is human.

11. (Currently Amended) The method of claim ~~[[1]]~~ 34, wherein the ~~mammal~~ subject in need of treatment has RNA inclusions in neuronal cells.

12-33. (Cancelled)

34. (Previously Presented) A method of treating myotonia in the muscle of a subject suffering from myotonia, comprising intramuscular injection of a recombinant adeno-associated virus (rAAV) vector comprising a promoter operably linked to a nucleic acid encoding a MBNL1 protein, wherein expression of the protein results in reducing myotonia in the muscle of the subject.